Bizzini B, Carlotti M, Fattal German M
Unité de Toxinologie Moléculaire, Institut Pasteur, Paris, France.
Biomed Pharmacother. 1992;46(10):491-4. doi: 10.1016/0753-3322(92)90007-t.
It is known that C granulosum-derived P40 immunomodulator displays strong anti-microbial effects in mice by the intravenous route. Since microbial contamination of humans occurs in many instances via the airways, the effect of P40 on infections was investigated when it was given intranasally or by aerosolization. In order to augment its bioavailability, P40 was derivatized by coupling with polylysine chains (P40-PL). The results showed that P40-PL exercised a significant protective effect, both by the intranasal route and by aerosolization on both influenza and K pneumoniae infections produced by aerosolization or intranasal instillation. Stimulation of the phagocytic capacity of alveolar macrophages by these types of treatment is likely to account for the increased resistance of mice toward microbial infections.
已知颗粒丙酸杆菌衍生的P40免疫调节剂通过静脉途径在小鼠中显示出强大的抗菌作用。由于人类的微生物污染在许多情况下是通过气道发生的，因此研究了经鼻内给药或雾化给药时P40对感染的影响。为了提高其生物利用度，通过与聚赖氨酸链偶联对P40进行衍生化（P40-PL）。结果表明，P40-PL通过鼻内途径和雾化对雾化或鼻内滴注产生的流感和肺炎克雷伯菌感染均具有显著的保护作用。通过这些类型的治疗刺激肺泡巨噬细胞的吞噬能力可能是小鼠对微生物感染抵抗力增强的原因。
